Terms: = Bone cancer AND PHOX2B, 8929
23 results:
1. Combined analysis of phox2b at two time points and its value for further risk stratification in high-risk neuroblastoma.
Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
[TBL] [Abstract] [Full Text] [Related]
2. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Asgharzadeh S; Marachelian A; Villablanca JG; Liu WY; Kennedy R; Sposto R; Naranjo A; Tenney S; Yu AL; Ozkaynak MF; Sondel PM; Park JR; Seeger RC
Pediatr Blood Cancer; 2022 Sep; 69(9):e29719. PubMed ID: 35441784
[TBL] [Abstract] [Full Text] [Related]
3. Opsoclonus-Myoclonus-Associated Neuroblastoma With bone Marrow Metastases: What Would Be the Best Treatment Option?
Gizhlaryan M; Aghabekyan T; Arakelyan T; Petrosyan M; Iskanyan S; Tamamyan G; Sargsyan L; Papyan R
Oncology (Williston Park); 2021 Oct; 35(10):665-667. PubMed ID: 34677924
[TBL] [Abstract] [Full Text] [Related]
4. The role of β-catenin and paired-like homeobox 2B (phox2b) expression in neuroblastoma patients; predictive and prognostic value.
El-Shazly SS; Hassan NM; Abdellateif MS; El Taweel MA; Abd-Elwahab N; Ebeid EN
Exp Mol Pathol; 2019 Oct; 110():104272. PubMed ID: 31220430
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
[TBL] [Abstract] [Full Text] [Related]
6. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
[TBL] [Abstract] [Full Text] [Related]
7. Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.
Corrias MV; Parodi S; Tchirkov A; Lammens T; Vicha A; Pasqualini C; Träger C; Yáñez Y; Dallorso S; Varesio L; Luksch R; Laureys G; Valteau-Couanet D; Canete A; Pöetschger U; Ladenstein R; Burchill SA
Pediatr Blood Cancer; 2018 Jul; 65(7):e27052. PubMed ID: 29603574
[TBL] [Abstract] [Full Text] [Related]
8. Expression of Five Neuroblastoma Genes in bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
Marachelian A; Villablanca JG; Liu CW; Liu B; Goodarzian F; Lai HA; Shimada H; Tran HC; Parra JA; Gallego R; Bedrossian N; Young S; Czarnecki S; Kennedy R; Weiss BD; Goldsmith K; Granger M; Matthay KK; Groshen S; Asgharzadeh S; Sposto R; Seeger RC
Clin Cancer Res; 2017 Sep; 23(18):5374-5383. PubMed ID: 28559462
[No Abstract] [Full Text] [Related]
9. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria bone Marrow Working Group.
Burchill SA; Beiske K; Shimada H; Ambros PF; Seeger R; Tytgat GA; Brock PR; Haber M; Park JR; Berthold F
Cancer; 2017 Apr; 123(7):1095-1105. PubMed ID: 27984660
[TBL] [Abstract] [Full Text] [Related]
10. phox2b is a suppressor of neuroblastoma metastasis.
Naftali O; Maman S; Meshel T; Sagi-Assif O; Ginat R; Witz IP
Oncotarget; 2016 Mar; 7(9):10627-37. PubMed ID: 26840262
[TBL] [Abstract] [Full Text] [Related]
11. Diagnostic utility of phox2b in primary and treated neuroblastoma and in neuroblastoma metastatic to the bone marrow.
Hata JL; Correa H; Krishnan C; Esbenshade AJ; Black JO; Chung DH; Mobley BC
Arch Pathol Lab Med; 2015 Apr; 139(4):543-6. PubMed ID: 25822764
[TBL] [Abstract] [Full Text] [Related]
12. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract] [Full Text] [Related]
13. bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
[TBL] [Abstract] [Full Text] [Related]
14. [Prognostic value of the determination of bone marrow lesion in patients with neuroblastoma based on the gene phox2b and TH expression].
Druĭ AE; Shorikov EV; Tsaur GA; Popov AM; Tuponogov SN; Savel'ëv LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2014; 60(2):57-62. PubMed ID: 24919263
[TBL] [Abstract] [Full Text] [Related]
15. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
[TBL] [Abstract] [Full Text] [Related]
16. Transcription factor-induced lineage programming of noradrenaline and motor neurons from embryonic stem cells.
Mong J; Panman L; Alekseenko Z; Kee N; Stanton LW; Ericson J; Perlmann T
Stem Cells; 2014 Mar; 32(3):609-22. PubMed ID: 24549637
[TBL] [Abstract] [Full Text] [Related]
17. Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Ora I; van Sluis PG; Bras J; den Ouden E; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Mol Diagn; 2012; 14(2):168-75. PubMed ID: 22251610
[TBL] [Abstract] [Full Text] [Related]
18. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Popov AM; Tuponogov SN; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
Vopr Onkol; 2012; 58(4):514-20. PubMed ID: 23607207
[TBL] [Abstract] [Full Text] [Related]
19. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
[TBL] [Abstract] [Full Text] [Related]
20. Lung-residing metastatic and dormant neuroblastoma cells.
Edry Botzer L; Maman S; Sagi-Assif O; Meshel T; Nevo I; Bäuerle T; Yron I; Witz IP
Am J Pathol; 2011 Jul; 179(1):524-36. PubMed ID: 21703429
[TBL] [Abstract] [Full Text] [Related]
[Next]
